Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.59 -1.59 (-3.30%)
Official Closing Price Updated: 4:10 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
74 75 Next >
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
With yields above 4%, these stocks could do a lot to boost your passive income stream 
Via The Motley Fool
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
Check Out What Whales Are Doing With BMY
Via Benzinga
Smart Money Is Betting Big In BMY Options
Via Benzinga
Smart Money Is Betting Big In BMY Options
Via Benzinga
Where Will Bristol Myers Squibb Be in 5 Years?
The drugmaker will go through key changes by the end of the decade. 
Via The Motley Fool
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
ETFs offer a good way to own a diversified portfolio of income-producing equities. 
Via The Motley Fool
Topics ETFs
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'
Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges and outlines cost-cutting measures, including a 7% workforce reduction. 
Via Benzinga
Topics Workforce
Exposures Layoff
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and... 
Via Benzinga
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity. 
Via InvestorPlace
Bristol-Myers Squibb Co: Is It A Buy?
As part of an ongoing series, we typically conduct an analysis on one of the companies in our screens each week. This week, we thought we’d take a look at one of the cheapest stocks in our screens:... 
Via Talk Markets
3 Stocks Retirees Should Absolutely Love
All of these stocks can provide steady income to retired investors. 
Via The Motley Fool
3 Biotech Stocks With Promising Drug Pipelines: August 2024
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval. 
Via InvestorPlace
Exposures Product Safety
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy... 
Via Benzinga
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts. 
Via The Motley Fool
MarketBeat Week in Review – 7/29 - 8/2
The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
The 3 Biggest Earnings Beats for Q2 as of August 1, 2024
The stocks serving up the biggest earnings beats may just go on to offer investors fabulous returns going forward. 
Via InvestorPlace
Topics Earnings
Exposures Financial
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
These cheap value stocks are priced right for any bargain hunters seeking deals in the market at the moment. 
Via InvestorPlace
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
The Top 3 Healthcare Stocks to Buy Now: Summer 2024
Investors should consider the long term prospects of the following three healthcare stocks as the U.S. population ages. 
Via InvestorPlace
Post-it Manufacturer 3M Sticks Landing While Ford Tanks: Biggest Beats And Misses From Earnings Season So Far
3M soared over 20% since it reported strong earnings on July 26, while Ford is down over 20% since its report on July 24. 
Via Benzinga
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)... 
Via Benzinga
Exposures COVID-19
Market Momentum: Your Weekly Financial Forecast
Originally published at VolumeLeaders What to expect for July 29- August 02, 2024 
Via Benzinga
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now?
A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giant's dividend program. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Healthcare Stocks Are Coming On Strong In July Led By Biotech
The biotech rally gained momentum in July with rotation out of technology stocks. 
Via Talk Markets
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.